Current perspectives in the management of treatment-resistant depression

Dialogues in Clinical Neuroscience

Volumn 6, Issue 1, 2004, Pages 53-60

  Parikh, Rajesh M ^a   Lebowitz, Barry D ^b  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant treatment; Management strategy; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; BUSPIRONE; CLOZAPINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PAROXETINE; PEMOLINE; PERGOLIDE; PINDOLOL; PRAMIPEXOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

BRAIN TOMOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; DISABILITY; DOSE RESPONSE; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR DEPRESSION; MORBIDITY; PRACTICE GUIDELINE; PSYCHIATRIC DIAGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 1842458468     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Murray JCL, Lopez AD. The Global Burden of Disease in 1990. Final results and their sensitivity to alternative epidemiological perspectives. Distant rates, age weights, and disability weights. In: Murray JCL, Lopez AD, eds. The Global Burden of Disease. Cambridge, Mass: Harvard University Press; 1996:247-296.
2. World Health Organization (WHO). World Health Report. Mental Health: New Understanding, New Hope. Geneva, Switzerland: WHO; 2002.
3. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology. 2003;28:552-557.
4. Nelsen MR, Dunner DL. Treatment resistance in unipolar depression and other disorders. Diagnostic concerns and treatment possibilities. Psychiatr Clin N Am. 1993;16:541-566.
5. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179-200.
6. Paykel ES. Epidemiology of refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD, eds. Refractory Depression: Current Strategies and Future Directions. New York, NY: John Wiley and Sons; 1994:3-7.
7. Sonawalla SB, Fava M. La depression resistante [Resistant depression]. In: Olié JP, Dalery J, Azorin JM, eds. Medicaments antipsychotiques. Paris, France: Pub Acanthe; 2001:459-465.
8. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097.
9. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855.
10. Kupfer DJ, Frank E. The interaction of drug and psychotherapy in the long-term treatment of depression. J Affect Disord. 2001;62:131-137.
11. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
12. Hall RC, Gardner ER, Popkin MK, Lecann AF, Stickney SK. Unrecognized physical illness prompting psychiatric admission: a prospective study. Am J Psychiatry 1981;138:629-635.
13. Ghoge H, Sharma S, Sonawalla S, Parikh R. Cerebrovascular diseases and depression. Curr Psychiatry Rep. 2003;5:231-238.
14. Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002;43:310-316.
15. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971.
16. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137.
17. Papakostas GI, Petersen T, Denninger J, et al. Somatic symptoms in treatment-resistant depression. Psychiatry Res. 2003;118:39-45.
18. Kaplan MJ, Klinetob NA. Childhood emotional trauma and chronic post-traumatic stress disorder in adult outpatients with treatment-resistant depression. J Nerv Ment Dis. 2000;188:596-601.
19. Schatzberg AF. Controversies in antidepressant therapy. J Clin Psychiatry. 1983;44(9 Pt 2):29-30.
20. Post R, Weiss S. The neurobiology of treatment-resistant mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Philadelphia, Pa: Lippincott-Raven; 1995:1115-1170.
21. 12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997;154:426-428.
22. Alpert JE, Fava M. Nutrition and depression: the role of folate. Nutr Rev. 1997;55:145-149.
23. Keitner GI, Ryan CE, Miller IW, et al. Recovery and major depression: factors associated with 12-month outcome. Am J Psychiatry. 1992;149:93-99.
24. Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry. 1998;172:527-532.
25. Shah PJ, Glabus MF, Goodwin GM, Ebmeier KP. Chronic, treatment-resistant depression and right fronto-striatal atrophy. Br J Psychiatry. 2002;180:434-440.
26. Hornig M, Mozley PD, Amsterdam JD. HMPAO SPECT brain imaging in treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21:1097-1114.
27. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8:1057-1061.
28. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse and relapse with SSRIs in major depression: a survey of current " next-step" practices. J Clin Psychiatry 2000;61:403-408.
29. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;15:1372-1374.
30. Rosenbaum JF, Fava M, Nierenberg AA, Sachs GS. Treatment-resistant mood disorders. In: Gabbard GO, ed. Treatment of Psychiatric Disorders. 3rd ed. Washington, DC: American Psychiatric Press; 2001;2:1307-1383.
31. Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry. 2003;64(suppl 2):14-18.
32. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19:427-434.
33. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158:1617-1622.
34. Lasser RA, Baldessarini RJ. Thyroid hormones in depressive disorders: a reappraisal of clinical utility. Harv Rev Psychiatry. 1997;4:291-305.
35. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15:217-222.
36. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry: a reconsideration. Arch Gen Psychiatry. 1987;44:286-295.
37. Lavretsky H, Kumar A. methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry. 2001;9:298-303.
38. Menza MA, Kaufman KR, Castellanos A. Modafanil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61:378-381.
39. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry. 1992;32:1-17.
40. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137-140.
41. Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry. 1998;59(suppl 12):41-45.
42. Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry. 1996;40:253-258.
43. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60:256-259.
44. Shelton R, Tollefson G, Tohen M, et al. The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. New Clinical Drug Evaluation Unit Program. Presented at 38th Annual Meeting, Boca Raton, Fla, June 1998.
45. Rosenbaum JF, Fava M, Nierenberg A. The Pharmacologic Treatment of Mood Disorders. Psychiatric Clinics of North America: Annual of Drug Therapy. Philadelphia, Pa: WB Saunders; 1994;1:17-50.
46. Nelson JC. Overcoming treatment resistance in depression. J Clin Psychiatry. 1998;59(suppl 16):13-19. Discussion. 1998;59(suppl 16):40-42.
47. Nelson JC. Overcoming treatment resistance in depression. J Clin Psychiatry. 1998;59(suppl 16):13-19. Discussion. 1998;59(suppl 16):40-42.
48. Rosenbaum JF, Fava M, Nierenberg A, Sachs G. Treatment-resistant mood disorders. In: Gabbard GO, ed. Treatments of Psychiatric Disorders. 2nd ed. Washington, DC: APPI; 1995;1:1276-1328.
49. Klapheke M. Potential drug-ECT interactions. Biol Ther Psychiatry. 1991;14:34-37.
50. Devanand DP, Fitzsimons L, Prudic J, et al. Subjective side-effects during electro-convulsive therapy. Convulsive Ther. 1995;11:232-240.
51. Janicak PG, Sharma RP, Israni TH, et al. Effects of unilateral-nondominant vs bilateral ECT on memory and depression: a preliminary report. Psychopharmacol Bull. 1991;79:353-357.
52. Weiner SJ, Ward TN, Ravaris CL. Headache and electro-convulsive therapy. Headache. 1994;34:155-159.
53. O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a CORE report. Am J Geriatr Psychiatry. 2001;9:382-390.
54. Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol. 2002;5:73-103.
55. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: 1-year outcomes. Biol Psychiatry. 2002;51:280-287.
56. Hornig-Rohan M, Wolkowitz OM, Amsterdam JD. Novel strategies for treatment-resistant depression. Psychiatr Clin N Am. 1996;19:387-405.
57. Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry. 2001;62(suppl 18):18-24
58. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs. 2001;15:765-776.
59. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rational and design. Controlled Clinical Trials. 2004. In press.
60. Rush AJ, Trivedi M, Fava M. Depression IV: STAR*D treatment trial for depression. [Images in Neuroscience]. Am J Psychiatry. 2003;160:237.
61. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50:792-801.